Prognostic value of copeptin and mid-regional proadrenomedullin in COVID-19-hospitalized patients.

ABSTRACT:

Background

Biomarkers are used for diagnosis, risk stratification and medical decisions. Copeptin and mid-regional proadrenomedullin (MR-proADM) are markers of stress and endothelial function, respectively, which have been studied in pneumonia, sepsis and septic shock. This study aimed to assess whether copeptin and MR-proADM could predict coronavirus disease 2019 (COVID-19) in-hospital outcomes, that is multi-system complications, length of stay and mortality.

Methods

Copeptin and MR-proADM were assessed at admission in 116 patients hospitalized with COVID-19. Data were retrospectively extracted from an online database. The primary endpoint was in-hospital mortality. The secondary endpoints were in-hospital complications, the composite outcome 'death, or admission to intens

SUBMITTER: Indirli R 

PROVIDER: S-EPMC9111431 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature